Lower Urinary Tract Symptoms and Overactive Bladder in a Large Cohort of Older Poles—A Representative Tele-Survey

Przydacz, Mikołaj; Gąsowski, Jerzy; Grodzicki, Tomasz; Chłosta, Piotr

doi:10.3390/jcm12082859

Cited by 5 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5). With the increasing global population of elderly people, the incidence of OABS due to prostatic hyperplasia has garnered substantial attention owing to its effects on QOL of elderly patients, particularly male patients, in terms of work productivity, emotional well-being, and sexuality [19]. OABS are closely related to the storage symptoms of BPH and LUTS.…”

Section: Pvr Urine Volumementioning

confidence: 99%

Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials

Wu,

Li,

Zhou

et al. 2024

Urol Int

View full text Add to dashboard Cite

Introduction: Overactive bladder symptoms (OABS) affect patients’ quality of life (QOL) worldwide. This pooled analysis compared the efficacy and safety of mirabegron add-on tamsulosin with those of tamsulosin add-on placebo in OABS treatment. Methods: PubMed, Embase, MEDLINE, and the Cochrane Controlled Trial Register databases were searched for randomized controlled trials (RCTs) examining the efficacy of mirabegron add-on therapy to tamsulosin in the treatment of OABS. Moreover, references from the selected studies were screened. Review Manager 5.4 was used to analyze data. Results: Four RCTs involving 1397 patients with OABS were selected. Of the total, 697 patients receiving mirabegron add-on tamsulosin constituted the experimental group and 700 patients receiving tamsulosin add-on placebo constituted the control group. The efficacy endpoints were as follows: mean number of micturition per day (mean difference [MD] = −0.26, 95% confidence interval [CI] = −0.41 to −0.10, P = 0.0001), urgency episodes per day (MD = −0.67, 95% CI = −1.02 to −0.32, P = 0.0002), urgency urinary incontinence (UUI) episodes per day (MD = −0.42, 95% CI = −0.66 to −0.19, P = 0.0005), mean volume voided/micturition (MD = 10.84, 95% CI = 4.97 to 16.71, P = 0.0003), total International Prostate Symptom Score (IPSS) (MD = −2.01, 95% CI = −4.02 to −0.01, P = 0.05), and IPSS QOL index (MD = −0.65, 95% CI = −0.94 to −0.35, P < 0.0001). Mirabegron therapy add-on therapy to tamsulosin was effective in treating patients with OABS. Moreover, mirabegron might reduce the total IPSS (MD = −2.01, 95% CI = −4.02 to −0.01, P = 0.05). The safety endpoint, treatment-emergent adverse events (odds ratio = 0.94, 95% CI = 0.78 to 1.13, P = 0.49), suggested that although mirabegron was well-tolerated, it possibly increased the post-void residual urine volume (MD = 10.28, 95% CI = 1.82 to 18.75, P = 0.02). Conclusion: Combination therapy using mirabegron and tamsulosin may be effective in treating patients with non-neurogenic OABS in terms of UUI episodes, total IPSS, and IPSS QOL index. However, its effectiveness must be verified by analyzing additional factors for OABS through further RCTs.

show abstract

Section: Pvr Urine Volumementioning

confidence: 99%

Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials

Wu,

Li,

Zhou

et al. 2024

Urol Int

View full text Add to dashboard Cite

show abstract

Polo‐like kinase 1 inhibition modulates urinary tract smooth muscle contraction and bladder cell transcriptional programs

Wang,

Guo,

Yisha

et al. 2024

Cytoskeleton

View full text Add to dashboard Cite

The serine/threonine kinase polo‐like kinase 1 (PLK1) is a master regulator of cell proliferation and contraction, but its physiological role in the lower urinary tract is unknown. We utilized transcriptomic programs of human bladder smooth muscle cells (hBSMCs), 3D bladder spheroid viability assays, and human ureterovesical junction contractility measurements to elucidate the impacts of PLK1 inhibition. This work reveals PLK1 reduction with the selective inhibitor TAK‐960 (500 nM) suppresses high K+‐evoked contractions of human urinary smooth muscle ex vivo while decreasing urothelial cell viability. Transcriptomic analysis of hBSMCs treated with TAK‐960 shows modulation of cell cycle and contraction pathways, specifically through altered expression of Cys2/His2‐type zinc finger transcription factors. In bladder spheroids, PLK1 inhibition also suppresses smooth muscle contraction protein filamin. Taken together, these findings establish PLK1 is a critical governor of urinary smooth muscle contraction and urothelial proliferation with implications for lower urinary tract disorders. Targeting PLK1 pharmacologically may therefore offer therapeutic potential to ameliorate hypercontractility and aberrant growth. Further elucidation of PLK1 signaling networks promises new insights into pathogenesis and much needed treatment advances for debilitating urinary symptoms.

show abstract

Intradetrusor OnabotulinumtoxinA outcomes for overactive bladder in older adults

Stading,

Hernandez,

Pacheco

et al. 2024

Continence

View full text Add to dashboard Cite

Lower Urinary Tract Symptoms and Overactive Bladder in a Large Cohort of Older Poles—A Representative Tele-Survey

Cited by 5 publications

References 26 publications

Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials

Mirabegron Add-On Tamsulosin for Men with Overactive Bladder Symptoms: A Pooled Analysis of Four Randomized Controlled Trials

Polo‐like kinase 1 inhibition modulates urinary tract smooth muscle contraction and bladder cell transcriptional programs

Intradetrusor OnabotulinumtoxinA outcomes for overactive bladder in older adults

Contact Info

Product

Resources

About